Bausch Health Companies (BHC) Liabilities and Shareholders Equity (2009 - 2026)
Bausch Health Companies (BHC) reported Liabilities and Shareholders Equity of $24.5 billion for Q1 2026, down 7.28% on a YoY basis from $26.4 billion in Q1 2025, and down 7.08% sequentially from $26.4 billion in Q4 2025.
Bausch Health Companies (BHC) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $24.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 7.28% year-over-year to $24.5 billion; the trailing twelve-month figure through Mar 2026 stood at $105.0 billion (down 0.97% YoY), and the FY2025 full-year result was $26.4 billion, down 0.59% from the prior year.
- Liabilities and Shareholders Equity slipped to $24.5 billion in Q1 2026, from $26.4 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $29.1 billion in Q1 2022 to a low of $24.5 billion in Q1 2026.
- A 5-year average of $26.6 billion and a median of $26.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Peak annual rise in Liabilities and Shareholders Equity reached 6.48% in 2023, while the deepest fall reached 12.53% in 2023.
- Tracing BHC's Liabilities and Shareholders Equity over 5 years: stood at $25.7 billion in 2022, then advanced by 6.48% to $27.4 billion in 2023, then decreased by 3.02% to $26.5 billion in 2024, then fell by 0.59% to $26.4 billion in 2025, then dropped by 7.08% to $24.5 billion in 2026.
- Business Quant data shows BHC's Liabilities and Shareholders Equity at $24.5 billion in Q1 2026, $26.4 billion in Q4 2025, and $26.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 24.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.50 Bn |
| Dec 31, 2025 | 26.37 Bn |
| Sep 30, 2025 | 26.82 Bn |
| Jun 30, 2025 | 27.27 Bn |
| Mar 31, 2025 | 26.42 Bn |
| Dec 31, 2024 | 26.52 Bn |
| Sep 30, 2024 | 26.54 Bn |
| Jun 30, 2024 | 26.50 Bn |
| Mar 31, 2024 | 26.91 Bn |
| Dec 31, 2023 | 27.35 Bn |
| Sep 30, 2023 | 27.06 Bn |
| Jun 30, 2023 | 25.50 Bn |
| Mar 31, 2023 | 25.45 Bn |
| Dec 31, 2022 | 25.69 Bn |
| Sep 30, 2022 | 26.30 Bn |
| Jun 30, 2022 | 28.17 Bn |
| Mar 31, 2022 | 29.09 Bn |
| Dec 31, 2021 | 29.20 Bn |
| Sep 30, 2021 | 29.25 Bn |
| Jun 30, 2021 | 30.04 Bn |